West Pharmaceutical debuts the Synchrony S1 prefillable syringe at Pharmapack 2026, enhancing biologics, vaccines and home-care support.
West Pharmaceutical (WST) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #1 (Strong Buy).
The heavy selling pressure might have exhausted for West Pharmaceutical (WST) as it is technically in oversold territory now. In addition to this technical measure, strong agreement among Wall Street analysts in revising earnings estimates higher indicates that the stock is ripe for a trend reversal.
WST is riding on surging GLP-1 demand and HVP expansion. Yet, pricing pressure, tariff risks and contract manufacturing headwinds cloud the near-term outlook.
The average of price targets set by Wall Street analysts indicates a potential upside of 26.4% in West Pharmaceutical (WST). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.
WST leans on strong HVP demand, rising GLP-1 exposure and Annex 1 tailwinds, even as pricing and device margins weigh on near-term performance.
West Pharmaceutical Services, Inc. (WST) Presents at Citi Annual Global Healthcare Conference 2025 Transcript
West Pharmaceutical Services is rated a buy, supported by strong Q3 results, raised guidance, and a resilient long-term growth thesis. WST's focus on high-value proprietary elastomer components and secular industry drivers, like GLP-1 demand, underpins robust margin and revenue growth. Risks include questionable capital allocation, recent insider selling during buybacks, and potential disruption from oral drug alternatives.
West Pharmaceutical Services, Inc. ( WST ) Stephens Annual Investment Conference 2025 November 20, 2025 12:00 PM EST Company Participants Robert McMahon - Senior VP & CFO Shane Campbell - SVP & Chief Proprietary Segment Officer John Sweeney - Head of Investor Relations Conference Call Participants Steven Etoch - Stephens Inc., Research Division Presentation Steven Etoch Stephens Inc., Research Division Welcome to day 3 of Stephens 2025 Investment Conference here at Nashville. I'm Mac Etoch, the Life Science Tools and Pharma Services Analyst.
West Pharmaceutical Services, Inc. ( WST ) Jefferies London Healthcare Conference 2025 November 18, 2025 5:00 AM EST Company Participants Robert McMahon - Senior VP & CFO Conference Call Participants David Windley - Jefferies LLC, Research Division Presentation David Windley Jefferies LLC, Research Division Good morning. I'm Dave Windley with Jefferies Healthcare Equity Research.
West Pharmaceutical Services, Inc. ( WST ) UBS Global Healthcare Conference 2025 November 11, 2025 9:30 AM EST Company Participants Robert McMahon - Senior VP & CFO Presentation Unknown Analyst Joining our next session is with West Pharma and joining me on stage from West is Bob McMahon. Well, Bob.
West Pharmaceutical's strong Q3 beat and raised EPS outlook highlight robust demand, FX tailwinds, and solid growth in Proprietary Products.